Thermo Fisher Scientific concludes acquisition of Sanofi New Jersey site

Published On 2025-09-03 05:00 GMT   |   Update On 2025-09-03 05:00 GMT
Advertisement

Waltham: Thermo Fisher Scientific Inc, has announced the completion of its acquisition of Sanofi's state-of-the-art sterile fill-finish and packaging site in Ridgefield, New Jersey, marking an expansion of the companies’ strategic partnership to enable additional U.S. drug product manufacturing.

The terms of the deal were not disclosed. The Ridgefield facility is now part of Thermo Fisher's pharma services business within its Laboratory Products and Biopharma Services segment.

Under the agreement, Thermo Fisher will continue to manufacture a portfolio of therapies for Sanofi at the Ridgefield site while expanding use of the site to meet the growing demand for U.S. manufacturing capacity from pharma and biotech customers.  

“We are excited to add Sanofi’s Ridgefield site to our network and welcome more than 200 highly experienced colleagues to Thermo Fisher,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. “Bringing this world-class facility and team into our network strengthens our U.S. manufacturing capabilities to better support pharmaceutical and biotech customers, while positioning us for future expansion."  

Advertisement

Read also: Thermo Fisher Scientific, Telangana Govt to establish Bioprocess Design Centre in Hyderabad

In August, Thermo Fisher Scientific also received approval from the U.S. Food and Drug Administration (FDA) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS (zongertinib tablets), a tyrosine kinase inhibitor (TKI), developed by Boehringer Ingelheim.

Thermo Fisher operates a global sterile fill-finish manufacturing network and now adds Ridgefield to its U.S. sites in Greenville, North Carolina and Plainville, Massachusetts. Its global team delivers an unrivaled combination of technologies, purchasing convenience and pharmaceutical services through its brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.  

Read also: Thermo Fisher gets USFDA nod for NGS-based Companion Diagnostic for new Non Small Cell Lung Cancer treatment

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News